News

Dekel’s product candidates target indications including chronic pain and inflammation. In addition to its cannabinoid-related R&D drug programs, Dekel holds the IP rights to a disposable, dose-controlled inhalation

Around 80 patients will be enrolled in the trial across three sites including The University of Texas MD Anderson Cancer Center, the Sarah Cannon Research Institute and the

The approval allows the use of the Cook Pharmica manufacturing facility in Bloomington, Indiana for the production of bulk rHuPH20, the active ingredient used in Hylenex, and the

Xiaflex is approved in the US, EU, Canada and Australia to treat adult DC patients with a palpable cord. Dupuytren’s contracture is a progressive hand disease that can

LAL Deficiency is a serious, under-diagnosed disease with significant morbidity and early mortality. A rolling submission enables completed portions of the application to be submitted and reviewed on

Fycompa is an oral medication and is the first FDA-approved non-competitive AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptor antagonist. Perampanel CIII was approved by the FDA in October 2012 and

The two firms have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds. As part of the deal, NewLink will receive $150m in

The US-based company has also agreed to carry out human clinical trials using its HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1) in the region. With

The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis. Novartis